US · ANAB
AnaptysBio, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Diego, CA 92121-5801
- Website
- anaptysbio.com
Price · as of 2024-12-31
$66.76
Market cap 1.52B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $42.24 | -36.73% |
| Intrinsic Value(DCF) | $12,983.49 | +19,348.01% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $0.19 | $1.16 | |||
| 2015 | $6.00 | $0.00 | |||
| 2016 | $23.20 | $67.58 | $39.11 | $6.82 | $0.00 |
| 2017 | $116.87 | $62.58 | $12.86 | $7.95 | $45.80 |
| 2018 | $63.74 | $44.39 | $15.64 | $7.22 | $99.20 |
| 2019 | $18.23 | $26.18 | $10.15 | $0.00 | $0.00 |
| 2020 | $21.35 | $159.81 | $83,483.52 | $10.88 | $0.00 |
| 2021 | $28.63 | $40.19 | $2,462.39 | $2.46 | $14.71 |
| 2022 | $22.37 | $25.27 | $4.63 | $0.00 | $329.19 |
| 2023 | $24.80 | $20.45 | $0.00 | $0.00 | $0.00 |
| 2024 | $16.34 | $42.24 | $7,606.04 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates AnaptysBio, Inc.'s (ANAB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $42.24
- Current price
- $66.76
- AI upside
- -36.73%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$12,983.49
+19,348.01% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ANAB | AnaptysBio, Inc. | $66.76 | 1.52B | -37% | +19,348% | — | — | -3.19 | 6.54 | 5.08 | -4.83 | — | 6.54 | -79.49% | -125.93% | -159.10% | -182.71% | 99.94% | -31.02% | 5.21 | -2.29 | 9.51 | 9.38 | -2.66 | -1579.00% | 43203.00% | 1158.00% | -29.26% | -2.98 | 117.98% | 0.00% | 0.00% | 0.10% | -3.90 | -3.30 | 4.91 | -1.16 |
| BBOT | BridgeBio Oncology Therap… | $10.03 | 802.29M | — | — | — | — | 23.73 | 0.96 | — | -2.21 | — | 0.96 | 0.00% | — | — | 8.06% | -86.47% | 7.80% | 0.00 | — | 10.40 | 9.05 | 0.02 | -2310000.00% | — | — | -0.42% | -4.07 | -0.82% | 0.00% | 0.00% | 0.98% | -2.21 | -233.87 | — | 17.57 |
| DNTH | Dianthus Therapeutics, In… | $55.19 | 2B | -29% | -75% | — | — | -9.42 | 2.27 | 128.39 | -5.19 | — | 2.27 | 100.00% | -1633.74% | -1362.77% | -32.60% | -273.59% | -30.71% | 0.00 | — | 15.22 | 14.96 | 0.21 | -6982.00% | 12063.00% | 11175.00% | -9.78% | -4.24 | -210.26% | 0.00% | 0.00% | 0.00% | -5.17 | -6.73 | 84.49 | 21.62 |
| KOD | Kodiak Sciences Inc. | $26.80 | 1.42B | — | — | — | — | -1.08 | 1.27 | — | -0.62 | — | 1.27 | 0.00% | — | — | -84.70% | -174.25% | -43.24% | 0.47 | — | 6.72 | 6.57 | 0.65 | -3260.00% | — | -3982.00% | -61.84% | -4.59 | -109.78% | 0.00% | 0.00% | 0.00% | -0.50 | -0.79 | — | -6.24 |
| MNMD | Mind Medicine (MindMed) I… | $17.47 | 1.32B | — | — | — | — | -4.43 | 1.99 | — | -2.21 | — | 2.17 | — | — | — | -68.01% | 1162.37% | -50.94% | 0.09 | -45.52 | 7.25 | 7.05 | 2.42 | -9385.00% | — | 2294.00% | -16.44% | -2.04 | 885.11% | 0.00% | 0.00% | 34.56% | -2.21 | -2.90 | — | 2.74 |
| NRIX | Nurix Therapeutics, Inc. | $15.97 | 1.38B | +65% | -49% | — | — | -5.52 | 2.71 | 17.39 | -3.77 | -93.55 | 2.71 | 77.55% | -340.16% | -314.90% | -49.63% | 1083.07% | -38.96% | 0.10 | — | 7.02 | 6.86 | 0.78 | 590.00% | 5395.00% | 4488.00% | -18.04% | -2.88 | 998.91% | 0.00% | 0.00% | 7.50% | -3.23 | -3.50 | 10.99 | 3.48 |
| OCS | Oculis Holding AG | $29.41 | 1.68B | — | — | — | — | -7.08 | 8.29 | 886.66 | -7.02 | — | 10.12 | -7492.27% | -10671.14% | -12503.94% | -102.85% | 682.30% | -73.23% | 0.02 | — | 2.37 | 2.25 | 0.36 | -2862.00% | — | -1144.00% | -7.85% | -1.07 | 445.69% | 0.00% | 0.00% | 0.00% | -6.98 | -10.70 | 744.55 | 3.05 |
| PHAT | Phathom Pharmaceuticals, … | $12.56 | 979.85M | +275% | +76,266% | — | — | -3.78 | -1.91 | 4.77 | -4.45 | — | -1.91 | 87.09% | -91.36% | -126.35% | 63.97% | 57.00% | -69.41% | -0.01 | -2.35 | 1.73 | 1.58 | 0.80 | -4272.00% | 21693.00% | -3743.00% | -19.98% | -1.26 | 59.50% | 0.00% | 0.00% | 46.07% | -4.43 | -4.24 | 4.05 | -8.21 |
| TSHA | Taysha Gene Therapies, In… | $4.53 | 1.24B | +543% | -85% | — | +183% | -4.90 | 6.12 | 52.53 | -4.11 | — | 6.12 | 100.00% | -1097.55% | -1071.62% | -121.94% | 1496.02% | -53.62% | 0.88 | -896.66 | 5.42 | 5.30 | 0.86 | -6284.00% | -4607.00% | 151.00% | -18.64% | -3.10 | 1334.73% | 0.00% | 0.00% | 0.00% | -3.96 | -4.43 | 43.43 | -3.26 |
| URGN | UroGen Pharma Ltd. | $21.70 | 1.02B | -0% | -82% | — | — | -3.32 | -47.83 | 4.66 | -3.23 | — | -47.83 | 90.18% | -107.06% | -140.35% | 342.83% | 86.07% | -54.68% | -14.02 | -7.73 | 6.01 | 5.59 | 0.51 | -1662.00% | 929.00% | 2676.00% | -23.05% | -2.11 | 86.32% | 0.00% | 0.00% | 12.59% | -3.18 | -3.17 | 3.40 | -2.93 |
| XNCR | Xencor, Inc. | $12.77 | 911.91M | +93% | -51% | -81% | — | -9.93 | 1.44 | 7.27 | -15.55 | — | 1.46 | 91.63% | -141.35% | -73.20% | -14.00% | -41.06% | -10.06% | 0.40 | -5.56 | 6.25 | 4.84 | -4.22 | -6536.00% | 1365.00% | -3362.00% | -15.14% | -1.41 | -31.98% | 0.00% | 0.00% | 0.00% | -4.11 | -5.28 | 5.82 | 1.18 |
About AnaptysBio, Inc.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
- CEO
- Daniel R. Faga
- Employees
- 136
- Beta
- 0.35
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($12,983.49 ÷ $66.76) − 1 = +19,348.01% (DCF, example).